Form 4: ANAB Chief Legal Officer Reports Equity Transactions

AnaptysBio's Chief Legal Officer, Eric J. Loumeau, reported the acquisition of new restricted stock units and stock options, alongside sales of common stock, some for tax obligations and others under a 10b5-1 plan.

Summary

• Eric J. Loumeau, Chief Legal Officer of AnaptysBio, Inc. (ANAB), reported multiple transactions involving the company's common stock and derivative securities.
• On January 6, 2026, 5,545 restricted stock units (RSUs) settled into common stock, increasing direct beneficial ownership to 18,796 shares.
• Also on January 6, 2026, Loumeau acquired 17,100 new RSUs and 23,200 stock options with an exercise price of $43.91.
• On January 7, 2026, a total of 9,639 shares of common stock were sold.
• Of the shares sold, 2,017 were to cover tax withholding obligations related to RSU vesting and settlement, at a price of $45.11 per share.
• An additional 7,622 shares were sold under a Rule 10b5-1 trading plan adopted on April 11, 2025, at weighted average prices ranging from $44.87 to $47.23 per share.
• Following these transactions, Loumeau's direct beneficial ownership of common stock is 9,157 shares, along with 22,645 RSUs and 23,200 stock options.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions, including the grant of new equity awards and planned sales of common stock. These are standard events for executives and do not inherently indicate a positive or negative sentiment regarding the company's performance or outlook.

Positives

• Acquisition of 17,100 new Restricted Stock Units (RSUs) on January 6, 2026, indicating continued long-term incentive for the Chief Legal Officer.
• Grant of 23,200 stock options on January 6, 2026, with an exercise price of $43.91, further aligning management interests with shareholder value.
• Settlement of 5,545 RSUs into common stock on January 6, 2026, converting contingent rights into direct equity ownership.

Negatives

• Sale of 9,639 shares of common stock on January 7, 2026, reducing the Chief Legal Officer's direct common stock holdings.
• A portion of the sales (2,017 shares) was specifically for tax withholding obligations, which is a non-discretionary reduction in direct ownership.

Future Outlook

The Chief Legal Officer's equity awards have defined vesting schedules: 5,545 RSUs vest annually starting January 6, 2024; 17,100 RSUs vest annually starting January 6, 2027; and 23,200 stock options vest 25% on January 6, 2027, with the remainder vesting monthly thereafter until fully vested by January 5, 2036.

Management Comments

• The sale of 2,017 shares was to cover tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a discretionary transaction.
• The other reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 11, 2025.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, common across all publicly traded companies. It reflects standard equity compensation practices and planned stock sales by executives, which are typical mechanisms for managing personal finances and tax obligations while adhering to insider trading rules.

Corporate Governance

Stakeholder Impact

• Shareholders: The transactions represent routine insider activity, including both equity awards and sales. While sales reduce direct insider holdings, the new awards demonstrate continued alignment of executive interests with long-term company performance.
• Employees: The grant of new equity awards to a key executive reinforces the company's compensation strategy, which typically includes performance-based incentives.

Next Steps

• Continued vesting of 5,545 Restricted Stock Units annually from January 6, 2024.
• Commencement of annual vesting for 17,100 Restricted Stock Units on January 6, 2027.
• Initial 25% vesting of 23,200 stock options on January 6, 2027, followed by monthly vesting until fully vested.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, including the grant of new equity compensation and planned sales of common stock for tax purposes and under a 10b5-1 plan. Such transactions are common and generally do not provide a strong signal for a change in investment recommendation. The acquisition of new equity awards indicates continued executive alignment, while the sales are largely pre-planned or for tax obligations, not necessarily reflecting a change in management's outlook on the company's prospects. Therefore, a 'hold' recommendation is appropriate as there is no new material information to warrant a change in investment thesis.

Keywords

ANAPTYSBIO, ANAB, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, 10b5-1 Plan, Chief Legal Officer, Share Sale, Vesting